/guid/9202a8c04000641f800000000484d8fb rename

Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP), is psychoactive drug and...

Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP), is psychoactive drug and research chemical of the piperidine chemical class which acts as a long-lasting stimulant via functioning as a norepinephrine-dopamine reuptake inhibitor (NDRI). Desoxypipradrol is closely related on a structural level to the compounds methylphenidate (Ritalin, Focalin, Concerta) and pipradrol (Meretran), all three of which share a similar pharmacological action. Of these three piperidines, desoxypipradrol has the longest elimination half-life, as it is a highly lipophilic molecule lacking polar functional groups that are typically targeted by metabolic enzymes. Methylphenidate, on the other hand, is a short-acting compound, as it possesses a methyl-ester moiety that is easily cleaved, forming a highly polar acid group, while pipradrol is intermediate in duration, possessing a hydroxyl group which can be conjugated (e.g. with glucuronide) to increase its hydrophilicity and facilitate excretion, but no easily metabolized groups. Desoxypipradrol was developed by the pharmaceutical company CIBA (now called Novartis) in the 1950s, and researched for applications such as the treatment of